Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer - Arix Bioscience

Close Navigation

About Strategy Team Portfolio Insights Media Contact

Overlay

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

28th September 2022

Portfolio

This post references, or is about Aura. Find out more by clicking below

Video

Cambridge, USA

Useful Tools

Download, print or share this article

Print

Print Article Email

Email

Print

Share Article